...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Medicine and Medical Research >Effect of Ramipril Treatment on Proteinuria and Advanced Glycation End Products in Type 2 Diabetes Mellitus Patients with Nephropathy: One Year Follow up Study
【24h】

Effect of Ramipril Treatment on Proteinuria and Advanced Glycation End Products in Type 2 Diabetes Mellitus Patients with Nephropathy: One Year Follow up Study

机译：雷米普利治疗对2型糖尿病肾病患者蛋白尿和糖基化终末产物的影响：一年随访研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: The present study was carried out to evaluate the effect of angiotensin converting enzyme inhibitor (ACEI) therapy on proteinuria and serum advanced glycation end products (AGEs) level in type 2 diabetes mellitus (T2DM) patients with nephropathy. Study Design: Single-arm prospective longitudinal study. Duration and Place of Study: The study subjects were enrolled from Diabetic and Nephrology clinic at University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India, between September 2013 and July 2014. Methodology: The study subjects comprised of clinically diagnosed T2DM patients (n = 75) with evidence of persistent micro-albuminuria (ACR; 30-299 mg/g creatinine) or overt albuminuria (ACR; ≥300 mg/g creatinine) tested on two separate occasions. These patients were treated with ACE inhibitor; ramipril (5 mg to 20 mg /day) for 12 months. Effectiveness was assessed based on change in urinary albumin/creatinine ratio (ACR) and serum AGEs level. Results: Ramipril treatment produced significant fall in log urinary ACR ( P <0.001) and significant reduction in serum AGEs level ( P <0.001) during 12 months follow up period as compared to baseline values. Also significant positive correlation between serum AGEs level and urinary ACR was observed at baseline. However, after one year follow up the serum AGEs level and urinary ACR did not correlate significantly. No significant change in serum creatinine and estimated glomerular filtration rate (eGFR) were observed after one year follow up. Conclusions: Apart from antiproteinuric action, ramipril treatment has been found to lower serum AGEs level that may eventually arrest vascular complications in T2DM patients with nephropathy.
机译：目的：本研究旨在评估血管紧张素转化酶抑制剂（ACEI）治疗对2型糖尿病（T2DM）肾病患者的蛋白尿和血清晚期糖基化终产物（AGEs）水平的影响。研究设计：单臂前瞻性纵向研究。研究的持续时间和地点：研究对象于2013年9月至2014年7月之间从印度大学医学院和印度古鲁·泰格·巴哈杜尔医院的糖尿病肾病门诊就诊。方法：研究对象包括经过临床诊断的T2DM患者（n = 75），并在两次单独的情况下进行了持续性微量白蛋白尿（ACR; 30-299 mg / g肌酐）或明显的白蛋白尿（ACR;≥300mg / g肌酐）的证据。这些患者接受了ACE抑制剂治疗。雷米普利（5 mg至20 mg /天）持续12个月。根据尿白蛋白/肌酐比值（ACR）和血清AGEs水平的变化评估疗效。结果：与基线值相比，在随访12个月期间，雷米普利治疗使对数尿ACR显着下降（P <0.001），血清AGEs水平显着降低（P <0.001）。在基线时还观察到血清AGEs水平与尿ACR之间显着正相关。然而，在一年的随访中，血清AGEs水平与尿液ACR没有显着相关性。随访一年后，血清肌酐和估计的肾小球滤过率（eGFR）均未见明显变化。结论：除了抗蛋白尿作用，雷米普利治疗还可以降低血清AGEs水平，这可能最终阻止T2DM肾病患者的血管并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号